Ligand Pharmaceuticals, Inc. (LGNXZ)
LGNXZ Stock Price Chart
Explore Ligand Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze LGNXZ price movements and trends.
LGNXZ Company Profile
Discover essential business fundamentals and corporate details for Ligand Pharmaceuticals, Inc. (LGNXZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
—
Employees
68.00
Website
http://www.ligand.comCEO
Todd C. Davis
Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
LGNXZ Financial Timeline
Browse a chronological timeline of Ligand Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
Earnings released on 7 Aug 2025
EPS came in at $0.88 falling short of the estimated $1.42 by -37.82%, while revenue for the quarter reached $47.63M , missing expectations by -18.87%.
Earnings released on 8 May 2025
EPS came in at -$2.21 falling short of the estimated $1.21 by -282.81%, while revenue for the quarter reached $45.33M , beating expectations by +2.32%.
Earnings released on 27 Feb 2025
EPS came in at -$1.70 , while revenue for the quarter reached $42.81M , beating expectations by +21.26%.
Earnings released on 7 Nov 2024
EPS came in at -$0.39 , while revenue for the quarter reached $51.81M , beating expectations by +32.81%.
Earnings released on 6 Aug 2024
EPS came in at -$2.88 , while revenue for the quarter reached $41.53M .
Earnings released on 7 May 2024
EPS came in at $4.75 , while revenue for the quarter reached $30.98M .
Earnings released on 14 Mar 2024
EPS came in at $1.03 , while revenue for the quarter reached $28.10M .
Earnings released on 27 Feb 2024
EPS came in at -$0.59 , while revenue for the quarter reached $32.87M .
Earnings released on 29 Jun 2023
EPS came in at $0.13 , while revenue for the quarter reached $26.37M .
Earnings released on 30 Mar 2023
EPS came in at $2.33 , while revenue for the quarter reached $43.98M .
Earnings released on 30 Dec 2022
EPS came in at -$1.04 , while revenue for the quarter reached $50.38M .
Earnings released on 8 Nov 2022
EPS came in at $0.02 , while revenue for the quarter reached $66.09M .
Earnings released on 9 Aug 2022
EPS came in at -$0.05 , while revenue for the quarter reached $57.42M .
Earnings released on 9 May 2022
EPS came in at -$0.91 , while revenue for the quarter reached $45.69M .
Earnings released on 28 Feb 2022
EPS came in at -$0.30 , while revenue for the quarter reached $72.47M .
Earnings released on 9 Nov 2021
EPS came in at $0.80 , while revenue for the quarter reached $64.83M .
Earnings released on 2 Aug 2021
EPS came in at $1.79 , while revenue for the quarter reached $84.68M .
Earnings released on 6 May 2021
EPS came in at $1.05 , while revenue for the quarter reached $55.15M .
Earnings released on 24 Feb 2021
Revenue for the quarter reached $186.42M .
Earnings released on 6 Nov 2020
EPS came in at -$1.03 , while revenue for the quarter reached $41.85M .
LGNXZ Stock Performance
Access detailed LGNXZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.